Division of Bausch Health Companies Inc.
Latest From Nicox Inc.
Shire's CEO says he sees scientific and technological advances as an opportunity to become the leading rare disease company. Ornskov also talked about the firm's debt-reduction and M&A strategy going forward.
The latest drug development news and US FDA highlights from our Performance Tracker.
Q4 device financing reached $902 million versus Q3’s $734 million, while device M&A dollar volume increased $19 billion, from Q3’s $4.9 billion. Diagnostics companies raised $750 million, an 85% rise over the previous quarter’s $405 million; although diagnostics M&A totaled just $1 billion, it was the most deal-active quarter of 2014 with 11 transactions.
Merck KGAA and Pfizer teamed up in an $850 million immunotherapy partnership; after fighting off Valeant’s efforts for months, Allergan ended up agreeing to a $65 billion acquisition by Actavis. Both biopharma and device financing were up vs. the previous month.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- Bausch Health Companies Inc.
- Senior Management
- Contact Info
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.